Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.80
NSPR's Cash-to-Debt is ranked higher than
52% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. NSPR: 2.80 )
Ranked among companies with meaningful Cash-to-Debt only.
NSPR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62  Med: 5026.6 Max: No Debt
Current: 2.8
Equity-to-Asset 0.43
NSPR's Equity-to-Asset is ranked lower than
73% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. NSPR: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NSPR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.52  Med: 0.43 Max: 0.78
Current: 0.43
-0.52
0.78
Piotroski F-Score: 5
Altman Z-Score: -21.50
Beneish M-Score: -4.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -403.75
NSPR's Operating Margin % is ranked lower than
88% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NSPR: -403.75 )
Ranked among companies with meaningful Operating Margin % only.
NSPR' s Operating Margin % Range Over the Past 10 Years
Min: -840.95  Med: -365.91 Max: -228.66
Current: -403.75
-840.95
-228.66
Net Margin % -446.67
NSPR's Net Margin % is ranked lower than
87% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. NSPR: -446.67 )
Ranked among companies with meaningful Net Margin % only.
NSPR' s Net Margin % Range Over the Past 10 Years
Min: -890.53  Med: -523.57 Max: -244.25
Current: -446.67
-890.53
-244.25
ROA % -121.47
NSPR's ROA % is ranked lower than
90% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NSPR: -121.47 )
Ranked among companies with meaningful ROA % only.
NSPR' s ROA % Range Over the Past 10 Years
Min: -436.36  Med: -230.92 Max: -80
Current: -121.47
-436.36
-80
ROC (Joel Greenblatt) % -1861.89
NSPR's ROC (Joel Greenblatt) % is ranked lower than
87% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. NSPR: -1861.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NSPR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8439.86  Med: -2238.93 Max: -1484.91
Current: -1861.89
-8439.86
-1484.91
3-Year Revenue Growth Rate -71.60
NSPR's 3-Year Revenue Growth Rate is ranked lower than
96% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. NSPR: -71.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NSPR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -71.6 Max: -41.4
Current: -71.6
3-Year EBITDA Growth Rate -73.80
NSPR's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. NSPR: -73.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NSPR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -73.8  Med: -9 Max: 685.3
Current: -73.8
-73.8
685.3
3-Year EPS without NRI Growth Rate -74.30
NSPR's 3-Year EPS without NRI Growth Rate is ranked lower than
97% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. NSPR: -74.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NSPR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.1 Max: 370.7
Current: -74.3
0
370.7
» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NSPR Guru Trades in

NSPR Guru Trades in

Q3 2016

NSPR Guru Trades in Q3 2016

Jim Simons 1,923,051 sh (New)
» More
Q4 2016

NSPR Guru Trades in Q4 2016

Jim Simons 109,742 sh (+42.67%)
» More
» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:BIAD, OTCPK:ACXA, OTCPK:ESMC, OTCPK:ECGI, OTCPK:VYCO, OTCPK:VRSEF, OTCPK:TMED, OTCBB:GTHP, OTCPK:IGNG, OTCPK:PETV, OTCPK:AIRW, OTCPK:MPHMF, NAS:MDGS, OTCPK:EQUR, NAS:SSH, OTCPK:ACAR, OTCPK:NUMD, OTCPK:PBIO, NAS:AHPI, NAS:PHMD » details
Traded in other countries:II2N.Germany,
InspireMD Inc together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard.

InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.

Ratios

vs
industry
vs
history
PB Ratio 0.34
NSPR's PB Ratio is ranked higher than
98% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. NSPR: 0.34 )
Ranked among companies with meaningful PB Ratio only.
NSPR' s PB Ratio Range Over the Past 10 Years
Min: 0.32  Med: 8.97 Max: 360.33
Current: 0.34
0.32
360.33
PS Ratio 0.27
NSPR's PS Ratio is ranked higher than
96% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. NSPR: 0.27 )
Ranked among companies with meaningful PS Ratio only.
NSPR' s PS Ratio Range Over the Past 10 Years
Min: 0.26  Med: 10.01 Max: 98.75
Current: 0.27
0.26
98.75
EV-to-EBIT 0.43
NSPR's EV-to-EBIT is ranked higher than
99% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. NSPR: 0.43 )
Ranked among companies with meaningful EV-to-EBIT only.
NSPR' s EV-to-EBIT Range Over the Past 10 Years
Min: -49.4  Med: -2.9 Max: 0.5
Current: 0.43
-49.4
0.5
EV-to-EBITDA 0.46
NSPR's EV-to-EBITDA is ranked higher than
98% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. NSPR: 0.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
NSPR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50  Med: -2.9 Max: 0.5
Current: 0.46
-50
0.5
Current Ratio 1.80
NSPR's Current Ratio is ranked lower than
65% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. NSPR: 1.80 )
Ranked among companies with meaningful Current Ratio only.
NSPR' s Current Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.67 Max: 4.68
Current: 1.8
0.68
4.68
Quick Ratio 1.69
NSPR's Quick Ratio is ranked higher than
51% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. NSPR: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
NSPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.67 Max: 4.28
Current: 1.69
0.57
4.28
Days Inventory 102.55
NSPR's Days Inventory is ranked higher than
63% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. NSPR: 102.55 )
Ranked among companies with meaningful Days Inventory only.
NSPR' s Days Inventory Range Over the Past 10 Years
Min: 102.55  Med: 135.33 Max: 315.56
Current: 102.55
102.55
315.56
Days Sales Outstanding 68.61
NSPR's Days Sales Outstanding is ranked lower than
53% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. NSPR: 68.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.99  Med: 82.25 Max: 138.85
Current: 68.61
63.99
138.85
Days Payable 125.95
NSPR's Days Payable is ranked higher than
79% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. NSPR: 125.95 )
Ranked among companies with meaningful Days Payable only.
NSPR' s Days Payable Range Over the Past 10 Years
Min: 71.71  Med: 112.28 Max: 132.86
Current: 125.95
71.71
132.86

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -119.50
NSPR's 3-Year Average Share Buyback Ratio is ranked lower than
96% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. NSPR: -119.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NSPR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -141  Med: -106.1 Max: -34.4
Current: -119.5
-141
-34.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.63
NSPR's Price-to-Net-Cash is ranked higher than
98% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.26 vs. NSPR: 0.63 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NSPR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.62  Med: 7.6 Max: 110.32
Current: 0.63
0.62
110.32
Price-to-Net-Current-Asset-Value 0.42
NSPR's Price-to-Net-Current-Asset-Value is ranked higher than
98% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. NSPR: 0.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NSPR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.41  Med: 5.42 Max: 24.94
Current: 0.42
0.41
24.94
Price-to-Tangible-Book 0.34
NSPR's Price-to-Tangible-Book is ranked higher than
98% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. NSPR: 0.34 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NSPR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.33  Med: 4.8 Max: 22.59
Current: 0.34
0.33
22.59
Price-to-Median-PS-Value 0.03
NSPR's Price-to-Median-PS-Value is ranked higher than
99% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. NSPR: 0.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NSPR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 0.89 Max: 2.72
Current: 0.03
0.03
2.72
Earnings Yield (Greenblatt) % 221.14
NSPR's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. NSPR: 221.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NSPR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 218.64  Med: 561.6 Max: 2327
Current: 221.14
218.64
2327

More Statistics

Revenue (TTM) (Mil) $1.89
EPS (TTM) $ -13.17
Beta1.29
Short Percentage of Float21.21%
52-Week Range $0.85 - 15.43
Shares Outstanding (Mil)1.47

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -0.37
EPS without NRI ($) -0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
Insiders Roundup: Sales on Facebook Mar 25 2016 
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
InspireMD's CGuard(TM) Carotid Embolic Prevention System to be Featured at ICCA Stroke 2017 in... Mar 23 2017
INSPIREMD, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events,... Mar 22 2017
InspireMD Repays Term Note Ahead of Schedule Mar 22 2017
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 21 2017
InspireMD, Inc. :NSPR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Hong Kong Mar 21 2017
InspireMD Announces CGuard Distribution Agreement for the Russian Federation Mar 20 2017
INSPIREMD, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments... Mar 15 2017
InspireMD Reports Continued Progress in the Transition of European Sales and Distribution Mar 15 2017
Dawson James Securities Announces the Completion of Public Offering with InspireMD Inc. for Gross... Mar 15 2017
InspireMD Announces Closing of Public Offering of Approximately $6.8 Million Mar 14 2017
InspireMD, Inc. :NSPR-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 09 2017
InspireMD Announces Pricing of Public Offering of up to $7.5 Million Mar 09 2017
INSPIREMD, INC. Financials Feb 22 2017
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Feb 21 2017
InspireMD Provides Year End Business Update; Reports Financial Results for the Fourth Quarter and... Feb 17 2017
INSPIREMD, INC. Files SEC form 10-K, Annual Report Feb 16 2017
InspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and... Feb 16 2017
InspireMD's CGuard(TM) Carotid Embolic Prevention System to be Featured at LINC 2017 Jan 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)